| Literature DB >> 14558185 |
William L Holden1, Juhaeri Juhaeri, Wanju Dai.
Abstract
This is the first part of a two-article series which will introduce the theory and practice of a proposed set of quantitative methods for benefit-risk analysis. Adjustments to number-needed-to-treat (NNT) analysis and a new method, minimum clinical efficacy (MCE) analysis are presented and critically discussed. The goal of these methods is to condense into a summary metric the benefit-risk profile of a product so that manufacturers, regulators, clinicians and patients can better understand and participate in risk management. A second article will present examples of these methods.Entities:
Mesh:
Year: 2003 PMID: 14558185 DOI: 10.1002/pds.887
Source DB: PubMed Journal: Pharmacoepidemiol Drug Saf ISSN: 1053-8569 Impact factor: 2.890